Home Banner

PRESS RELEASE: Macrophage Pharma raises £9 million in Series A financing and acquires immune-oncology technology platform

Macrophage Pharma is an immuno-oncology company focussed on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. Macrophage Pharma’s technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body’s natural immune system to fight cancer.

Macrophage Pharma’s novel Esterase Sensitive Motif (ESM) technology has delivered agents which are being developed to induce targeted and durable anti-tumour immune responses and provide next-generation immunotherapy with broad utility in oncology.

Macrophage Pharma’s approach is to create a more hostile environment for tumour growth by:

  • Reprogramming tumour macrophages to stimulate the anti-tumour immune response
  • Reversing immunosuppression in the tumour microenvironment
  • Converting tolerogenic dendritic cells to effective antigen presenting cells

The company is exploiting a unique and proprietary knowledge base to unleash the full therapeutic potential of ESM technology in immuno-oncology.

target

OUR APPROACH

Macrophage Pharma’s primary goal is to develop a new generation of powerful small-molecule immuno-oncology drugs which inhibit the ability of tumour polarised macrophages to release immunosuppressive cytokines.

more details...

target

ESM TECHNOLOGY

The foundation of Macrophage Pharma’s approach is its proprietary Esterase Sensitive Motif (ESM) technology. The technology involves the use of specifically designed amino acid ester motifs that are selectively hydrolysed.

more details...

target

R&D PROJECTS

Macrophage Pharma’s lead programme is focused on the novel macrophage targeted p38 MAPK inhibitor, CHR-6155, supported by a strong package of non-clinical immuno-oncology and early safety pharmacology data.

more details...